Andere Sprachen Carna Biosciences, Inc.

Aktien

A0NHD5

JP3220550002

4572

Markt geschlossen - Japan Exchange Andere Börsenplätze 08:00:00 06.06.2024			% 5 Tage	% 1. Jan.
392 ^JPY	-0.76%		+1.29%	-24.90%

07.03.	Fresh Tracks Therapeutics, Inc. und Carna Biosciences, Inc. schließen Vereinbarung zur Beendigung der Lizenz ab	CI
2023	Carna Biosciences, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2023	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Carna Biosciences, Inc. announced that it expects to receive ¥362.07 million in funding from Athos Capital Limited	15.05.
Fresh Tracks Therapeutics, Inc. and Carna Biosciences, Inc. Enters into Termination of License Agreement	07.03.
Carna Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10.05.23
Carna Biosciences, Inc. announced that it has received ¥11.209315 million in funding from Cantor Fitzgerald & Co.	08.12.22
Carna Biosciences, Inc. announced that it expects to receive Ã‘11.209315 million in funding from Cantor Fitzgerald & Co.	22.11.22
Carna Biosciences, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022	10.05.22
Brickell Biotech Obtains Exclusive Rights to Carna Biosciences' Inhibitor Portfolio Targeting Inflammatory Diseases	02.02.22
Brickell Biotech, Inc. Enters into an Exclusive License Agreement with Carna Biosciences, Inc	02.02.22
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Six Months Ended June 30, 2021	06.08.21
Carna Biosciences, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2021	06.08.21
Carna Biosciences, Inc. announced that it has received ¥14.67507 million in funding from Cantor Fitzgerald & Co.	30.07.21
Carna Biosciences, Inc. announced that it expects to receive ¥14.67507 million in funding from Cantor Fitzgerald & Co.	14.07.21
Carna Biosciences, Inc. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2020	12.02.21
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020	12.02.21
Carna Biosciences, Inc. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2020	09.11.20
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020	09.11.20
Carna Biosciences, Inc. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2020	12.05.20
Carna Biosciences, Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2020	12.05.20
Carna Biosciences, Inc. Announces Consolidated and Non-Consolidated Earnings Results for the Year Ended December 31, 2019; Provides Consolidated Earnings Guidance for the Full Year Ending December 31, 2020	07.02.20
Carna Biosciences, Inc. Provides Earnings Forecast for the Fiscal Year Ending December 31, 2019	09.01.20

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Carna Biosciences, Inc.

Aktien

A0NHD5

JP3220550002

4572

Andere Sprachen

Filter